

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5864635

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	CHUGAI PHARMA MANUFACTURING CO., LTD.	12/04/2019
RECEIVING PARTY DATA		
Name:	CHUGAI SEIYAKU KABUSHIKI KAISHA	
Street Address:	5-1, UKIMA 5-CHOME	
Internal Address:	KITA-KU	
City:	TOKYO	
State/Country:	JAPAN	
Postal Code:	1158543	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16612212
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	khoover@nixonvan.com, myparalegalkb@gmail.com, vbartels@nixonvan.com, shill@nixonvan.com, anorris@nixonvan.com	
Correspondent Name:	NIXON & VANDERHYE P.C.	
Address Line 1:	901 N. GLEBE ROAD, SUITE 1100	
Address Line 4:	ARLINGTON, VIRGINIA 22203	
ATTORNEY DOCKET NUMBER:	6663.0125	
NAME OF SUBMITTER:	KENLEY K. HOOVER	
SIGNATURE:	/Kenley K. Hoover/	
DATE SIGNED:	12/12/2019	
Total Attachments: 2		
source=Assignment_Chugai Pharma to Chugai Seiyaku_6663.0125_C1-A1703P-US (002)#page1.tif		
source=Assignment_Chugai Pharma to Chugai Seiyaku_6663.0125_C1-A1703P-US (002)#page2.tif		

ASSIGNMENT

In consideration of the sum of one dollar (\$1.00) or equivalent and other good and valuable consideration, receipt of which is hereby acknowledged, Chugai Pharma Manufacturing Co., Ltd., whose mailing address is 5-1, Ukima 5-chome, Kita-ku, Tokyo 1158543 JAPAN (hereafter referred to as the "Assignor"), hereby sells and assigns to Chugai Seiyaku Kabushiki Kaisha, a corporation formed under the laws of Japan, whose mailing address is 5-1, Ukima 5-chome, Kita-ku, Tokyo 1158543 JAPAN, (hereafter referred to as the "Assignee"), one hundred percent (100%) of its right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **"METHOD FOR PRODUCING CYCLIC ORGANIC COMPOUND"** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of November 8, 2019 (also known as United States Application No. 16/612,212, which is the U.S. National Phase of International Application No. PCT/JP2018/018265, International Filing Date May 11, 2018), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patents that claim the benefit of the patent application listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient and further to perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

The Assignor agrees to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The Assignor hereby represents that Assignor has full right to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict therewith.

The Assignor hereby grants the patent practitioners associated with **CUSTOMER NUMBER 23117** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The Assignor hereby represents that Assignor understands that the patent practitioners associated with **CUSTOMER NUMBER 23117** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the Assignor.

SIGNED on behalf of the said ASSIGNOR,

Chugai Pharma Manufacturing Co., Ltd.

By: Shinya Takuma

Name: Shinya Takuma

Title: President

Date: December 4, 2019